Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists.

Abstract:

INTRODUCTION:The appetite stimulating effects of melanin-concentrating hormone (MCH) continues to be of high interest, and there is substantial support to investigate the use of MCH 1-receptor antagonists for the treatment of obesity. Other areas of potential use for MCH 1-receptor antagonists include depression and anxiety. There are, to date, no clinical proof of concept data, and efforts are ongoing for the discovery of novel MCH 1-receptor antagonists, as evidenced by the number of patent applications published over the last 5 years. AREAS COVERED:This review covers the patent literature on MCH 1-receptor antagonists from January 2006 to November 2010. The emphasis is on disclosed biological data, especially in vivo data, of exemplified compounds. Wherever possible, selectivity towards undesired pharmacology is analysed. EXPERT OPINION:Over the years, different approaches have been taken to overcome the undesired effects of MCH 1-receptor antagonists, such as interactions with the hERG channel. Many programmes have faced difficulties and, to date, only a few compounds have progressed into humans. From this point of view, the MCH 1-receptor is regarded as a difficult target, and whether newer programmes will be successful depends, to a large extent, on their selectivity.

journal_name

Expert Opin Ther Pat

authors

Johansson A

doi

10.1517/13543776.2011.575063

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

905-25

issue

6

eissn

1354-3776

issn

1744-7674

journal_volume

21

pub_type

杂志文章,评审
  • Inhibitors of melanogenesis: a patent review (2009 - 2014).

    abstract:INTRODUCTION:Melanogenesis is the process of producing the melanin pigment, in which a series of chemical and enzymatic pathways are involved. Modulation at any level of this process would become an important approach in the treatment of hyper- or hypopigmentation-related diseases. Since hyperpigmentation covers import...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2015.1039985

    authors: Pillaiyar T,Manickam M,Jung SH

    更新日期:2015-07-01 00:00:00

  • Acylhydrazone derivatives: a patent review.

    abstract:INTRODUCTION:The N-acylhydrazone (NAH) moiety has been characterized as a privileged structure, capable of providing ligands points for more than one type of bioreceptor. Modifications of the subunits bonded to its acyl and imine functions resulted in several derivatives, which modulate a great diversity of molecular t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.959491

    authors: Maia Rdo C,Tesch R,Fraga CA

    更新日期:2014-11-01 00:00:00

  • Solid lipid nanoparticles: a review on recent perspectives and patents.

    abstract::Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for drug delivery. Surface modifications of SLNs may further provide unique features t...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2020.1720649

    authors: Paliwal R,Paliwal SR,Kenwat R,Kurmi BD,Sahu MK

    更新日期:2020-03-01 00:00:00

  • Caffeic acid derivatives, analogs and applications: a patent review (2009-2013).

    abstract:INTRODUCTION:Caffeic acid (CA) is broadly distributed in several species of the plant kingdom and is widely consumed in human diet. CA and derivatives have been extensively studied in the past years, which unveiled a broad spectrum of biological activities and potential therapeutic applications. As a result, there has ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.959492

    authors: Silva T,Oliveira C,Borges F

    更新日期:2014-11-01 00:00:00

  • Growth hormone secretagogue receptor antagonists.

    abstract::The patent claims peptidic/nonpeptidic inhibitors of the ghrelin receptor, the growth hormone secretagogue receptor (GHSR) 1A. Among these compounds, it was disclosed that the addition in some compounds of a GlyMetAla tripeptide at the N-terminus of the ghrelin peptide agonists converts them into ghrelin receptor anta...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2012.684946

    authors: Costantino L

    更新日期:2012-06-01 00:00:00

  • Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).

    abstract:INTRODUCTION:Since exendin-4 (exenatide) was approved for diabetes therapy in 2005, several exendin analogs have been developed for the treatment of type 2 diabetes mellitus. As exenatide is a relatively short-acting injectable agent, major approaches have focused on developing long-acting exendin analogs to improve pa...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2016.1192130

    authors: Park EJ,Lim SM,Lee KC,Na DH

    更新日期:2016-07-01 00:00:00

  • Sulfonamide inhibitors: a patent review 2013-present.

    abstract:INTRODUCTION:Sulfonamide compounds are significant class of synthetic bacteriostatic antibiotics still which used today for the therapy of bacterial infections and those caused by other microorganisms. They are also known as sulfa drugs and were the main source of therapy against bacterial infections before the introdu...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1487400

    authors: Gulçin İ,Taslimi P

    更新日期:2018-07-01 00:00:00

  • Lessons from black pepper: piperine and derivatives thereof.

    abstract:INTRODUCTION:Piperine is a simple and pungent alkaloid found in the seeds of black pepper (Piper nigrum). Following its isolation and full characterization, the biological properties of piperine have been extensively studied, and piperine-like derivatives have shown an interesting range of pharmacological activities. I...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2016.1118057

    authors: Chavarria D,Silva T,Magalhães e Silva D,Remião F,Borges F

    更新日期:2016-01-01 00:00:00

  • Developments around the bioactive diketopiperazines: a patent review.

    abstract:INTRODUCTION:2,5-Diketopiperazines (DKPs) are cyclic dipeptides from two amino acids with or without further structural modifications in DKP nucleus. These DKPs demonstrated attractive bioactive diversity and potential in drug discovery. AREAS COVERED:This review summarized those bioactive DKPs in patents, and provide...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.828036

    authors: Wang Y,Wang P,Ma H,Zhu W

    更新日期:2013-11-01 00:00:00

  • Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present).

    abstract:INTRODUCTION:Over the past three years numerous patents and patent applications have been published relating to scientific advances in the use of the green tea polyphenol epigallocatechin gallate (EGCG) (the most abundant, and bioactive compound in green tea) and its analogs as anticancer agents. EGCG affects multiple ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.743993

    authors: Landis-Piwowar K,Chen D,Foldes R,Chan TH,Dou QP

    更新日期:2013-02-01 00:00:00

  • ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents.

    abstract:INTRODUCTION:The bacterial topoisomerases DNA gyrase and topoisomerase IV are validated targets for development of novel antibacterial agents. Fluoroquinolones inhibit the catalytic GyrA and/or ParC(GrlA) subunit and have been commonly used, although these have toxicity liabilities that restrict their use. The ATPase G...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2019.1575362

    authors: Durcik M,Tomašič T,Zidar N,Zega A,Kikelj D,Mašič LP,Ilaš J

    更新日期:2019-03-01 00:00:00

  • Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).

    abstract:INTRODUCTION:The non-receptor tyrosine kinase, inducible tyrosine kinase (Itk), plays an important role in thymus(T)-cell signalling and the production of pro-inflammatory cytokines. Itk, and the other Tec family members, Rlk and Tec, are viewed as attractive drug targets for new agents for the treatment of autoimmune ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.936381

    authors: Norman P

    更新日期:2014-09-01 00:00:00

  • Retinoid X receptor ligands: a patent review (2007 - 2013).

    abstract:INTRODUCTION:Retinoid X receptors (RXRs) are nuclear receptors that act as ligand-dependent transcription factors. RXRs function as homodimers or as heterodimers with other nuclear receptors, such as retinoic acid receptors, PPARs, liver X receptors, farnesoid X receptor, vitamin D receptor or thyroid hormone receptors...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2014.880692

    authors: Yamada S,Kakuta H

    更新日期:2014-04-01 00:00:00

  • Indazole derivatives and their therapeutic applications: a patent review (2013-2017).

    abstract:INTRODUCTION:Indazoles are heterocyclic moieties rarely found in nature. They are nitrogen containing chemical compounds composed of a pyrazole ring condensed with a benzene ring. Various indazole derivatives have been described with a wide variety of biological activities. This has aroused great interest in the develo...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1472240

    authors: Denya I,Malan SF,Joubert J

    更新日期:2018-06-01 00:00:00

  • A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033.

    abstract::This application claims salts and crystalline forms of a previously disclosed DP2 receptor antagonist (2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxy-phenyl]acetic acid (1)). It also claims compositions containing the free acid and its salts, especially the sodium salt and their us...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.636738

    authors: Norman P

    更新日期:2011-12-01 00:00:00

  • A decade of nutraceutical patents: where are we now in 2018?

    abstract:INTRODUCTION:In the last 10 years, nutraceuticals have grown in interest to researchers, industry, and consumers and are now familiar in the collective imagination as a tool for preventing the onset of a disease. Often nutraceuticals are confused with biologically active phytochemicals/botanicals which can have health ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1552260

    authors: Daliu P,Santini A,Novellino E

    更新日期:2018-12-01 00:00:00

  • Tryptase inhibitors: a patent review.

    abstract:INTRODUCTION:Tryptase is one of the main serine-proteinases located in the secretory granules of mast cells, and is released through degranulation, which is involved in the pathogenesis of allergic inflammatory disease, cardiovascular diseases, lung fibrosis and tumor. Therefore, inhibitors targeting tryptase may repre...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1322064

    authors: Ni WW,Cao MD,Huang W,Meng L,Wei JF

    更新日期:2017-08-01 00:00:00

  • New patented histone deacetylase inhibitors.

    abstract:IMPORTANCE OF THE FIELD:Following FDA approval of vorinostat in 2006, several novel HDAC inhibitors (HDACis) have entered clinical trials, and there are numerous published patent applications claiming novel HDACis which were optimized as potential drug candidates, designed for regional or systemic release, and created ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543770903393789

    authors: Wang H,Dymock BW

    更新日期:2009-12-01 00:00:00

  • QSAR modelling: a therapeutic patent review 2010-present.

    abstract:INTRODUCTION:Quantitative Structure-Activity Relationship (QSAR) models are becoming one of the most interesting fields for developing therapeutics and therapeutics related patents. At present, QSAR methodologies comprise a series of possibilities, including joining forces with machine learning methods and increasing e...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2018.1475560

    authors: Halder AK,Moura AS,Cordeiro MNDS

    更新日期:2018-06-01 00:00:00

  • Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications.

    abstract:IMPORTANCE OF THE FIELD:Nonsteroidal estrogens have been known since the 1930s. However, the relatively recent (1996) discovery of estrogen receptor subtype beta (ERbeta) suggested a possible paradigm shift away from SERM-like selectivity. Selective ERbeta agonism would potentially allow expansion of estrogenic targeti...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543771003657164

    authors: Mohler ML,Narayanan R,Coss CC,Hu K,He Y,Wu Z,Hong SS,Hwang DJ,Miller DD,Dalton JT

    更新日期:2010-04-01 00:00:00

  • Orexin research: patent news from 2016.

    abstract:INTRODUCTION:The orexin system consists of two G-protein-coupled receptors, orexin 1 and orexin 2 and two endogenous ligands, orexin A and orexin B . It is evolutionarily highly conserved. It is involved in the promotion of wakefulness as well as in anxiety and addictive disorders. In addition, its activation via the O...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1080/13543776.2017.1344221

    authors: Boss C,Roch C

    更新日期:2017-10-01 00:00:00

  • An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present).

    abstract:INTRODUCTION:Monoacylglycerol lipase (MAGL) belongs to the endocannabinoid system and is responsible for the inactivation of endocannabinoid 2-arachidonoylglycerol. Importantly, it was found that MAGL degradation of lipids in cancer cells enhances the availability of free fatty acids for new cellular membrane formation...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2021.1841166

    authors: Bononi G,Poli G,Rizzolio F,Tuccinardi T,Macchia M,Minutolo F,Granchi C

    更新日期:2020-11-01 00:00:00

  • 5-Lipoxygenase inhibitors: a review of recent developments and patents.

    abstract:IMPORTANCE TO THE FIELD:Leukotrienes (LTs) are pivotal lipid mediators of inflammation and allergy and results from recent studies also suggest roles of LTs in cardiovascular diseases, cancer and osteoporosis. 5-Lipoxygenase (5-LO) catalyzes the first step in the biosynthesis of LTs from arachidonic acid, and based on ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543771003602012

    authors: Pergola C,Werz O

    更新日期:2010-03-01 00:00:00

  • Parthenogenetically activated human oocytes and parthenogenetic embryonic stem cells: US20100233143.

    abstract:BACKGROUND:The application (US20100233143) is in the field of embryonic stems cells (ESCs) and the generation of ESCs from parthenogenetically activated human oocytes. OBJECTIVE:It aims at determining optimal conditions for parthenogenetically activating human oocytes. METHODS:Oocytes isolated from female donors were...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2011.581230

    authors: Taupin P

    更新日期:2011-08-01 00:00:00

  • Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells US2015011543 (a1): a patent evaluation.

    abstract:INTRODUCTION:There is an unmet need of strategies for ex-vivo expansion of hematopoetic stem cells (HSCs) without loss of their primitive nature or stemness. We evaluate here a patent that attempts to address this need via key small molecules 1 and 40 that possess a pyrimido[4,5-b]indole core. Areas covered: (i) Discus...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2017.1360281

    authors: Agarwal S,Agarwal H,Zaware N

    更新日期:2017-11-01 00:00:00

  • Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents.

    abstract::In addition to its central role in haemostasis and wound healing, thrombin activates platelets and smooth muscle cells by proteolytic activation of cell surface protease-activated receptor-1 (PAR-1), which is also known as the thrombin receptor. Thrombin is the most potent activator of human platelets and, as such, a ...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.16.4.493

    authors: Chackalamannil S,Xia Y

    更新日期:2006-04-01 00:00:00

  • Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.

    abstract:INTRODUCTION:There has been research on anticancer strategies which focus on disrupting a single malignant protein. One of the strategies is the inhibition of one protein, heat shock protein 90 (Hsp90). There are many reasons why Hsp90 protein is targeted by anticancer agents: maintenance of cellular homeostasis in org...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/13543776.2013.780597

    authors: Kim T,Keum G,Pae AN

    更新日期:2013-08-01 00:00:00

  • The challenges of joint performance to method patents.

    abstract:INTRODUCTION:Biotech patents are facing increasingly stern challenges. The patent statue holds that a multi-step method patent is not directly infringed unless all steps are carried out and attributed to a single entity. When separate steps are performed jointly by two or more parties, those parties are liable for divi...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1080/13543776.2017.1301930

    authors: Chen FC

    更新日期:2017-04-01 00:00:00

  • Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225).

    abstract:BACKGROUND:Many polycationic cell penetrating peptides (CPPs), alternatively named protein transduction domains, have been used for the efficient intracellular delivery of biologically active agents. Patent WO2008/082885 relates to the properties and proposed biomedical applications of a CPP and putative-related sequen...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章,评审

    doi:10.1517/17530050902824829

    authors: Howl J,Jones S

    更新日期:2009-09-01 00:00:00

  • Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.

    abstract::In recent years, the involvement of the Hedgehog (Hh) signaling pathway in various human diseases and dysfunctions has been clearly demonstrated. Smoothened (Smo), one of the upstream signal transducers, has been the most druggable target of the Hh pathway. However, the emergence of resistance to Smo inhibitors and th...

    journal_title:Expert opinion on therapeutic patents

    pub_type: 杂志文章

    doi:10.1517/13543776.2016.1132309

    authors: Manetti F,Petricci E

    更新日期:2016-01-01 00:00:00